Genetic mutations in acute myeloid leukemia that influence clinical decisions

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Purpose of review A plethora of studies over the past two decades have identified many genes that are recurrently mutated in acute myeloid leukemia (AML). Although great advances have been made in understanding the role of these mutated genes in AML disease pathogenesis, to date relatively few have been demonstrated to have direct clinical relevance. Recent findings Genomic techniques have allowed for the identification of many mutated genes that appear to drive disease pathogenesis and prognosis in AML. Integrated analyses examining the co-occurrence of these genes in well annotated AML patient cohorts has helped to significantly refine prognostic models, allowing for a more nuanced selection of patients for optimal postremission therapies. Furthermore, there are emerging data that gene mutations may be useful to select patients for optimal doses and/or modalities of upfront AML therapy. Finally, mutated genes themselves hold promise as therapeutic targets, as supported by strong preclinical studies. Summary Recent advances in our knowledge of the molecular genetics of AML have significantly improved our tools for clinical decision-making and promise to identify new therapies for patients.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalCurrent opinion in hematology
Issue number2
StatePublished - Mar 2014
Externally publishedYes


  • Acute myeloid leukemia
  • Gene mutations
  • Molecular genetics
  • Novel therapeutics
  • Post-remission therapy

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Genetic mutations in acute myeloid leukemia that influence clinical decisions'. Together they form a unique fingerprint.

Cite this